Diversity, Equity, and Inclusion in the Drug Development Lifecycle Meeting

Menu Back to Diversity-Equity-and-Inclusion-in-the-Drug-Development-Lifecycle-Meeting

Overview

DIA’s Diversity, Equity, and Inclusion in the Drug Development Lifecycle Meeting will lead the way in sharing knowledge and fostering coalitions to build greater diversity, equity, and inclusion in the drug development lifecycle. Moving beyond describing the problems that exist in this space, the meeting will emphasize approaches and solutions in which our field has been investing. The meeting will include interactive and compelling discussions and exercises that will lead to a better understanding of how we can improve as an industry to encourage accountability and sustainability of efforts. An important purpose of the meeting is to advance dialogue among thought leaders from industry, clinical research sites, patient engagement, academia, FDA, and public policy to spur additional ideas to move the field forward.

This program has been developed in collaboration with the Diversity in Life Sciences Community.

Keynote Address Announced!

Robert Fullilove, EdD, Professor and Associate Dean, University of Columbia

Robert E. Fullilove, EdD is the Associate Dean for Community and Minority Affairs, Professor of Clinical Sociomedical Sciences and the co-director of the Cities Research Group. Dr Fullilove has authored numerous articles in the area of minority health. From 1995 to 2001, he served on the Board of Health Promotion and Disease Prevention at the Institute of Medicine (IOM) at the National Academy of Sciences. Since 1996, he has served on five IOM study committees that have produced reports on a variety of topics including substance abuse and addiction, HIV/AIDS, tuberculosis, and damp indoor spaces and health. In 2003 he was designated a National Associate of the National Academies of Science. In 1998 he was appointed to the Advisory Committee on HIV and STD Prevention (ACHSP) at the Centers for Disease Control, and in July, 2000, he became the committee's co-chair. Finally, between 2004-2007, he served on the National Advisory Council for the National Center for Complementary and Alternative Medicine at the National Institutes of Health [NIH]. Since 2010, he has been teaching public health courses in six New York State prisons that are part of the Bard College Prison Initiative (BPI) and serves as the Senior Advisor to BPI's public health program. Dr Fullilove serves on the editorial boards of the journals Sexually Transmitted Diseases, and the Journal of Public Health Policy. He has been awarded the Distinguished Teaching Award at the Mailman School of Public Health three times (in 1995, 2001, and 2013), and in May, 2002, he was awarded an honorary doctorate from Bank Street College of Education.

Who should attend?

Clinical Research
Clinical Operations
Data transparency/data sharing
Diversity, Equity and Inclusion
Health Outcomes
Medical Affairs and Communication
Patient Advocacy
Patient Engagement/Patient Support
Professional Education, Training and Development
Public Policy
Research and Development
Regulatory Affairs
Strategic Planning

Learning objectives

At the conclusion of this activity, participants should be able to:

Recognize how to engage and be proactive to the needs of diverse communities to build trust and combat misinformation
Identify strategies that work towards efforts of diversity, equity and inclusion with relation to the drug development lifecycle
Restate dialogue regarding the importance of genomics in discovery science and early clinical development
Apply how to engage Instiutional Review Boards (IRBs) and Independent Ethics Committees (IECs) on diversity, equity, and inclusion efforts within clinical trials and throughout the drug development lifecycle
Explain the conscious decision making it takes for a company to pursue diversity in clinical trials
Evaluate the challenges that impact diversity recruitment, enrollment, and retention in clinical trials
Describe FDA efforts to advance the inclusion of minorities and women in clinical trials
Identify industry efforts that support clinical trial diversity
Explain clinical research site activities that advance clinical trial diversity through community engagement
Discuss how to engage and support health equity and access during the post-marketing phase of the drug development lifecycle

Program Committee

Monique Adams, PhD, MS • Director, Clinical Innovation Lead
Janssen, United States
Richardae Araojo, PharmD, MS • Associate Commissioner for Minority Health, Director, Office of Minority Health
FDA, United States
Dyan Bryson, MBA • Patient Engagement Strategist/Patient Advocate
Inspired Health Strategies, United States
Robert Fullilove, EdD • Associate Dean, Community and Minority Affairs
Columbia University, United States
Diana Foster, BSN, PhD, MSN • CEO, Total Clinical Trial Management; Vice President, Strategy and Development
Society for Clinical Research Sites, United States
Mustafa Syed • Treasurer, DIA Student Chapter
St. Johns University, United States
Amy Sitnick, MA • Vice President, Marketing
Greenphire, United States
Charlotte Jones-Burton, MD, MS • Vice President
Otsuka Pharmaceutical, United States
Adaeze Enekwechi, PhD • Board Member
Alliance for Health Policy, United States